AI Verdict
GILD has stronger fundamentals based on our AI analysis.
ABBV vs GILD Fundamental Comparison
| Metric | ABBV | GILD |
|---|---|---|
| Revenue | $61.2B | $29.4B |
| Net Income | $4.2B | $8.5B |
| Net Margin | 6.9% | 28.9% |
| ROE | N/A | 37.5% |
| ROA | 3.2% | 14.4% |
| Current Ratio | 0.67x | 1.55x |
| Debt/Equity | N/A | 1.10x |
| EPS | $2.36 | $6.78 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ABBV vs GILD: Frequently Asked Questions
Is ABBV or GILD a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), GILD has stronger fundamentals. ABBV is rated HOLD (70% confidence) while GILD is rated BUY (82% confidence). This is not investment advice.
How does ABBV compare to GILD fundamentally?
AbbVie Inc. has ROE of N/A vs GILEAD SCIENCES, INC.'s 37.5%. Net margins are 6.9% vs 28.9% respectively.
Which stock pays higher dividends, ABBV or GILD?
ABBV has a dividend yield of N/A or no dividend while GILD has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ABBV or GILD for long term?
For long-term investing, consider that ABBV has HOLD rating with 70% confidence, while GILD has BUY rating with 82% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ABBV vs GILD?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ABBV vs GILD, the AI consensus favors GILD based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.